Adjust Font Size:

The MiStent® SES is an investigational drug-eluting stent in the clinical stage of development that has been designed to optimize healing. Read more. Euro - PCR Meeting, May 15, 2012 Presentation: DESSOLVE I: Twelve Month Clinical and Imaging Results from the FIH Trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System Presentation: Assessment of vascular response at 4, 6 and 8 months after the implantation of absorbable-coated sirolimus-eluting stents: an optical coherence tomography sub-study from the first-in-man DESSOLVE I trial		November 6, 2012 — Micell Technologies Announces Issuance of Core Technology Patent Read more. October 23 2012 — Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES Read more.		Micell Technologies is bringing together the clinical advantages of a drug-eluting stent with the long-term safety and stability of a bare metal stent. The resulting drug-delivery device is intended to redefine the field of interventional cardiology. Read more. Micell published in the Journal of Controlled Release on the enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug. Read more.